Unknown

Dataset Information

0

Serum beta-secretase 1 (BACE1) activity as candidate biomarker for late-onset Alzheimer's disease.

ABSTRACT: Beta-secretase (BACE1) is a key enzyme in the formation of amyloid-?; its activity/concentration is increased in brain and cerebrospinal fluid of patients with late-onset Alzheimer's disease (LOAD). Since BACE1 was found also in blood, we evaluated its potential as peripheral biomarker. To this aim, serum BACE1 activity was assessed in 115 subjects with LOAD and 151 controls. We found that BACE1 changed across groups (p < 0.001) with a 25% increase in LOAD versus controls. High levels of BACE1 (IV quartile) were independently associated with the diagnosis of LOAD (OR 2.8; 1.4-5.7). Diagnostic accuracy was 76% for LOAD. Our data suggest that increased BACE1 activity in serum may represent a potential biomarker for LOAD. Additional studies are needed to confirm the usefulness of BACE1, alone or in combination with other markers, in discriminating patients and predicting LOAD onset and progression.

SUBMITTER: Cervellati C 

PROVIDER: S-EPMC7031490 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Beta-secretase (BACE1) is a key enzyme in the formation of amyloid-β; its activity/concentration is increased in brain and cerebrospinal fluid of patients with late-onset Alzheimer's disease (LOAD). Since BACE1 was found also in blood, we evaluated its potential as peripheral biomarker. To this aim, serum BACE1 activity was assessed in 115 subjects with LOAD and 151 controls. We found that BACE1 changed across groups (p < 0.001) with a 25% increase in LOAD versus controls. High levels of BACE1 (  ...[more]

Similar Datasets

Unknown The β-Secretase BACE1 in Alzheimer's Disease.
| S-EPMC7533042 | biostudies-literature
Unknown Targeting the β secretase BACE1 for Alzheimer's disease therapy.
| S-EPMC4086426 | biostudies-literature
Unknown BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease.
| S-EPMC4159447 | biostudies-literature
Unknown Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer's Disease β Secretase, BACE1.
| S-EPMC8067017 | biostudies-literature
Unknown QSAR Classification Models for Predicting the Activity of Inhibitors of Beta-Secretase (BACE1) Associated with Alzheimer's Disease.
| S-EPMC6591229 | biostudies-literature
Unknown Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity.
| S-EPMC2748890 | biostudies-literature
Unknown Increased Serum Beta-Secretase 1 Activity is an Early Marker of Alzheimer's Disease.
| S-EPMC9198762 | biostudies-literature
Unknown LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease.
| S-EPMC1635650 | biostudies-literature
Unknown Increased blood BACE1 activity as a potential common pathogenic factor of vascular dementia and late onset Alzheimer's disease.
| S-EPMC7486910 | biostudies-literature
Unknown A Glycosaminoglycan Extract from Portunus pelagicus Inhibits BACE1, the β Secretase Implicated in Alzheimer's Disease.
| S-EPMC6562973 | biostudies-literature